M&A, Partnerships & Ecosystem Models in Biopharma
Why the Future of Biologics Will Depend as Much on Partnerships as on Molecules
Surbhi Gupta, Industry Principal, Healthcare & Life Sciences, Frost & Sullivan
The article will address how biopharma companies are combining manufacturing scale, regulatory collaboration, skilled talent, funding access, and public-private partnerships to strengthen biologics ecosystems, while also assessing China’s growing influence as an innovation hub, partner market, and competitive force in next-generation therapeutics, using selected APAC examples and recent market shifts.
Biopharma deal-making is entering a more disciplined phase. The industry is still looking outward to growth, but the model has changed. Large acquisitions remain important, yet companies are increasingly using a broader set of tools: licensing, co-development, manufacturing partnerships, regional supply agreements, public-private funding and targeted capability acquisitions.
This shift is particularly visible in Asia-Pacific. The region is no longer just a source of lower-cost manufacturing or future commercial demand. It is becoming a more complete biologics ecosystem, combining discovery platforms, clinical development scale, specialist manufacturing, regulatory reform, skilled talent and government-backed infrastructure. For global biopharma companies, APAC is moving from a downstream market to an early strategic partner.
The new playbook is not about owning every capability. It is about knowing where each capability should sit, how to share risk, and how to connect innovation with manufacturing, regulation and market access. China is central to this story, but South Korea, India, Japan, Singapore and Southeast Asia are also shaping the region’s next phase.
From transactions to ecosystems
Biopharma partnerships are becoming less transactional and more integrated. In the past, a large pharma company might license a promising asset, outsource manufacturing later, and manage regulatory strategy separately. That approach is becoming harder to sustain complex biologics.
Bispecific antibodies, antibody-drug conjugates, cell therapies and gene therapies require earlier decisions around process development, analytics, quality systems and manufacturing geography. A molecule can look attractive in early clinical development but lose value if scale-up is uncertain or if supply risk is too concentrated. As a result, business development teams are now assessing assets alongside their manufacturing route, regulatory pathway and regional execution plan.
This is where APAC is gaining relevance. The region offers not just assets, but ecosystems. China brings a rapidly expanding innovation base. South Korea brings biologics manufacturing scale and execution discipline. India brings biosimilars, vaccines, complex generics and cost-efficient development. Japan brings high-quality science and regulatory maturity. Singapore and parts of Southeast Asia offer neutral, well-governed hubs for regional coordination, talent and manufacturing.
The strategic question for companies is no longer whether APAC matters. It is which APAC market should play which role in a global biologics model.
China’s rise as an innovation partner
China’s role in global biopharma has changed quickly. Its companies are now producing assets and platforms that global pharma companies see as relevant to core portfolio strategy. This is especially clear in oncology, immunology, respiratory disease, obesity and metabolic disorders.
Recent partnerships involving AstraZeneca and CSPC, GSK and Hengrui, and AbbVie and RemeGen show how China-origin assets are being integrated into global pipelines. These are not simple regional licensing deals. They typically involve ex-China or ex-Greater China rights, staged milestone structures, and options to expand collaboration as evidence develops. This allows the global partner to access promising innovation without taking full acquisition risk, while the Chinese company retains domestic value and gains international development reach.
The appeal of China is not only cost. It is speed, clinical activity, platform ambition and a large domestic market that allows companies to generate early development experience. Chinese biotechs have also become more commercially flexible. Many are willing to structure deals around territory splits, option rights, co- development responsibilities and milestone-heavy economics. That flexibility has made China a more attractive partner at a time when large pharma companies face patent cliffs and pressure to rebuild pipelines efficiently.
At the same time, China’s growing influence brings new complexity. Cross-border partnerships now need sharper diligence around data, intellectual property, manufacturing location, supply continuity and geopolitical exposure. The direction, however, is not a simple retreat from China. It is a more selective and carefully governed form of collaboration. Companies still want China-origin innovation, but they want deal structures that can withstand political, regulatory and supply-chain scrutiny.
China is therefore both a partner market and a competitive force. It offers global pharma a faster route into differentiated science, while also creating companies that can compete internationally in next-generation therapeutics.
Manufacturing scale becomes strategic capital
In biologics, manufacturing has become a strategic asset. Capacity, geography and quality systems can determine whether a partnership scales successfully. This is why contract development and manufacturing organisations are no longer viewed only as vendors. In many cases, they are ecosystem partners.
Samsung Biologics’ acquisition of GSK’s Rockville, Maryland manufacturing facility is a useful example. The transaction gives Samsung Biologics its first US manufacturing site and adds regional capacity outside Korea. This strengthens its ability to support global sponsors that want manufacturing redundancy, proximity to regulated markets and reduced exposure to supply-chain disruption.
The move also reflects a broader pattern. APAC-based manufacturers are becoming global operators. Their value is no longer tied only to large plants in Asia. Sponsors increasingly want partners that can combine scale with geographic flexibility, inspection readiness and technology transfer discipline.
WuXi Biologics reflects another part of this trend. Its 2025 results showed strong demand for integrated biologics projects, particularly in bispecific antibodies and antibody-drug conjugates. The important point is not just the number of projects, but the nature of the work. Complex modalities require tight integration between discovery, cell-line development, process optimisation, analytical characterisation, clinical supply and commercial manufacturing.
This is why integrated research-development-manufacturing models are gaining ground. They reduce handover points, compress timelines and help sponsors manage technical risk earlier. In the next phase of biologics, manufacturing excellence will not sit behind innovation. It will be part of innovation.
South Korea links scale with platform science
South Korea is one of the clearest examples of an APAC ecosystem moving beyond its original strengths. The country has long been associated with biosimilars and large-scale biologics manufacturing. That remains important, but Korean biotechs are now attracting global partners for platform technologies and novel therapeutic approaches.
The GSK-ABL Bio collaboration illustrates this shift. ABL Bio’s Grabody-B platform is designed to help molecules cross the blood-brain barrier, one of the major obstacles in treating neurological diseases. For GSK, the partnership offers access to enabling technology. For ABL Bio, it brings global development, manufacturing and commercialisation reach.
This type of partnership shows how Korean biotech is moving into higher-value science while still benefiting from the country’s manufacturing reputation. Korea’s broader ecosystem also benefits from strong government support, hospital networks, clinical trial capability and a skilled workforce. Public-private initiatives in vaccines and pandemic preparedness further strengthen its global credibility.
South Korea’s advantage is execution. It has the infrastructure, discipline and industrial base to scale biologics. As more Korean companies develop differentiated platforms, the country is likely to become more important not only as a manufacturing location, but also as a source of partnerable innovation.
India’s access-led innovation model
India’s biopharma model is different. It is not yet producing the same volume of globally licensed novel biologics as China, but it has powerful advantages in affordability, scale and regulated-market execution. These strengths are increasingly relevant as biologics costs rise and healthcare systems demand more sustainable access.
Biocon is a good example of India’s direction. The company is expanding its biosimilar oncology portfolio and building a broader position across insulin, biosimilars and complex peptide opportunities. This sits at the intersection of manufacturing scale, affordability and global access.
India’s opportunity is likely to be access-led before it becomes discovery-led at scale. Biosimilars, vaccines, complex generics, peptides and biologics manufacturing are areas where Indian companies can build global relevance. Over time, public funding, start-up support and academic-industry collaboration can help move more Indian science towards novel assets.
BIRAC and related government initiatives are important in this context. They help early-stage biotech companies bridge the funding gap between academic research and investable development. For India, the challenge is not talent availability. The challenge is converting talent into globally competitive platforms and products. That will require stronger translational funding, more specialised biologics infrastructure, and better links between start-ups, large pharma companies and contract manufacturers.
India’s strength is that it understands scale and access. If it can connect those strengths to higher-value biologics innovation, it will occupy a distinct position in the APAC ecosystem.
Japan and Singapore strengthen the trust layer
Not every ecosystem contribution is measured by deal size. In advanced biologics, trust is equally important. Companies need confidence in regulatory systems, data standards, quality expectations and post-approval oversight.
Japan is working to make its regulatory system more outward facing. PMDA’s international offices, including its Washington DC presence, are intended to support earlier dialogue with overseas innovators and improve understanding of Japanese regulatory requirements. This matters because Japan has often been seen as a later-stage market in global development plans. Stronger regulatory engagement can help foreign biotechs consider Japan earlier, while supporting Japanese companies that want to globalise their own assets.
Singapore plays a different but complementary role. It remains one of APAC’s most trusted locations for regional headquarters, clinical coordination, advanced manufacturing and biomedical research. Its appeal lies in political stability, strong intellectual property protection, regulatory quality and access to regional talent. For companies managing China exposure or building multi-market Asia strategies, Singapore provides a neutral operating base.
Southeast Asia is also trying to reduce fragmentation. ASEAN’s pharmaceutical regulatory policy aims to harmonise requirements and deepen collaboration between national regulators. Progress will be gradual, but even partial convergence can make multi-country development and market access more practical. For sponsors, a more predictable Southeast Asian regulatory environment would strengthen the region’s value as both a patient-access market and a development platform.
What comes next
APAC’s biopharma landscape is becoming more specialised and more connected. China is supplying globally relevant assets and platforms. South Korea is combining biologics scale with platform science. India is building an access-led biologics and biosimilars model. Japan is strengthening regulatory engagement. Singapore and Southeast Asia are supporting regional coordination, talent and market access.
For global biopharma companies, the lesson is clear. APAC should not be considered only after an asset is ready for launch. It should be part of early business development, manufacturing strategy, clinical planning and regulatory design.
The companies that benefit most will be those that treat partnerships as ecosystem-building tools, not isolated transactions. In the next decade of biologics, success will depend on connecting science, capital, capacity, regulation and access across trusted partners. APAC is increasingly where those connections are being built.
Surbhi Gupta is an Industry Principal at Frost & Sullivan with extensive experience in global pharmaceutical and biotech market research and consulting. She leads the Biopharma Therapeutics program, focusing on next-generation modalities and precision medicine. Her work spans market analytics, forecasting, competitive benchmarking, and strategy support for biopharma clients globally.
